Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations

Controversy exists regarding the pathogenic or predictive role of anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in patients with multiple sclerosis (MS). Four immunopathological patterns (IP) have been recognized in early active MS lesions, suggesting heterogeneous pathogenic mechanisms....

Full description

Saved in:
Bibliographic Details
Published in:Multiple sclerosis 2007-01, Vol.13 (1), p.7-16
Main Authors: Pittock, S J, Reindl, M, Achenbach, S, Berger, T, Bruck, W, Konig, F, Morales, Y, Lassmann, H, Bryant, S, Moore, S B, Keegan, B M, Lucchinetti, C F
Format: Article
Language:English
Subjects:
Autoantibodies - blood
Biological and medical sciences
Biomarkers - blood
Blotting, Western
Cohort Studies
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
Demyelinating Diseases - genetics
Demyelinating Diseases - immunology
Demyelinating Diseases - pathology
Enzyme-Linked Immunosorbent Assay
Genotype
HLA-DR2 Antigen - genetics
Humans
Immunomodulators
Medical sciences
Multiple Sclerosis - genetics
Multiple Sclerosis - immunology
Multiple Sclerosis - pathology
Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis
Myelin Proteins
Myelin-Associated Glycoprotein - immunology
Myelin-Oligodendrocyte Glycoprotein
Neurology
Pharmacology. Drug treatments
Plasmapheresis
Predictive Value of Tests
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Controversy exists regarding the pathogenic or predictive role of anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in patients with multiple sclerosis (MS). Four immunopathological patterns (IP) have been recognized in early active MS lesions, suggesting heterogeneous pathogenic mechanisms. Whether MOG antibodies contribute to this pathological heterogeneity and potentially serve as biomarkers to identify specific pathological patterns is unknown. Here we report the frequencies of antibodies to human recombinant MOG (identified by Western blot and enzymelinked immunoabsorbent assay (ELISA)) in patients with pathologically proven demyelinating disease, and investigate whether antibody status is associated with clinical course, HLA-DR2 genotype, IP or treatment response to plasmapheresis. The biopsy cohort consisted of 72 patients: 12 pattern I, 43 pattern II and 17 pattern III. No association was found between MOG antibody status and conversion to clinically definite MS, DR-2 status, IP or response to plasmapheresis. There was poor agreement between Western blot and ELISA (kappa=0.07 for MOG IgM). Fluctuations in antibody seropositivity were seen for 3/4 patients tested serially by Western blot. This study does not support a pathologic pattern-specific role for MOG-antibodies. Variable MOG-antibody status on serial measurements, coupled with the lack of Western blot and ELISA correlations, raises concern regarding the use of MOG-antibody as an MS biomarker and underscores the need for methodological consensus.
ISSN:1352-4585
1477-0970
DOI:10.1177/1352458506072189